Nektar Therapeutics
NASDAQ:NKTR
Intrinsic Value
Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. [ Read More ]
The intrinsic value of one NKTR stock under the Base Case scenario is 1.9074 USD. Compared to the current market price of 0.9342 USD, Nektar Therapeutics is Undervalued by 51%.
Valuation Backtest
Nektar Therapeutics
Run backtest to discover the historical profit from buying and selling NKTR stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Our AI Assistant is coming soon! Stay tuned and thank you for your interest!
Provide an overview
of Nektar Therapeutics's business.
What risks and challenges
does Nektar Therapeutics face in the near future?
Summarize the latest earnings report
of Nektar Therapeutics.
Provide P/E
for Nektar Therapeutics and its competitors.
Balance Sheet Decomposition
Nektar Therapeutics
Current Assets | 330.7m |
Cash & Short-Term Investments | 303.6m |
Receivables | 1.2m |
Other Current Assets | 25.9m |
Non-Current Assets | 67.3m |
Long-Term Investments | 25.8m |
PP&E | 36.9m |
Other Non-Current Assets | 4.6m |
Current Liabilities | 51.3m |
Accounts Payable | 9.8m |
Accrued Liabilities | 41.4m |
Non-Current Liabilities | 215.8m |
Other Non-Current Liabilities | 215.8m |
Earnings Waterfall
Nektar Therapeutics
Revenue
|
90.1m
USD
|
Cost of Revenue
|
-33.8m
USD
|
Gross Profit
|
56.4m
USD
|
Operating Expenses
|
-191.6m
USD
|
Operating Income
|
-135.2m
USD
|
Other Expenses
|
-140.8m
USD
|
Net Income
|
-276.1m
USD
|
Free Cash Flow Analysis
Nektar Therapeutics
What is Free Cash Flow?
NKTR Profitability Score
Profitability Due Diligence
Nektar Therapeutics's profitability score is 16/100. The higher the profitability score, the more profitable the company is.
Score
Nektar Therapeutics's profitability score is 16/100. The higher the profitability score, the more profitable the company is.
NKTR Solvency Score
Solvency Due Diligence
Nektar Therapeutics's solvency score is 55/100. The higher the solvency score, the more solvent the company is.
Score
Nektar Therapeutics's solvency score is 55/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
NKTR Price Targets Summary
Nektar Therapeutics
According to Wall Street analysts, the average 1-year price target for NKTR is 1.02 USD with a low forecast of 1.01 USD and a high forecast of 1.05 USD.
Ownership
NKTR Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
NKTR Price
Nektar Therapeutics
Average Annual Return | -40% |
Standard Deviation of Annual Returns | 30.71% |
Max Drawdown | -99% |
Market Capitalization | 178.8m USD |
Shares Outstanding | 183 618 000 |
Percentage of Shares Shorted | 2.34% |
NKTR News
Last Important Events
Nektar Therapeutics
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Nektar Therapeutics
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. The company is headquartered in San Francisco, California and currently employs 740 full-time employees. The firm's research and development pipeline of new investigational drugs includes potential therapies for oncology, immunology and virology. In oncology, it is studying several immuno-oncology (I-O) drug candidates, including bempegaldesleukin, NKTR-255 and NKTR-262. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In autoimmune disorders, its IL-2 T-regulatory cell stimulator NKTR-358 is being clinically studied in systemic lupus erythematosus, ulcerative colitis, psoriasis and atopic dermatitis. Its programs in virology area include studying bempegaldesleukin in treating individuals affected with COVID-19, and a preclinical research collaboration with Gilead Sciences Inc. (Gilead) to test the combination of NKTR-255.
Contact
IPO
Employees
Officers
The intrinsic value of one NKTR stock under the Base Case scenario is 1.9074 USD.
Compared to the current market price of 0.9342 USD, Nektar Therapeutics is Undervalued by 51%.